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ABSTRACT 
BACKGROUND : 
        Cerebral venous thrombosis (CVT) is a life threatening condition with 
varied clinical presentations. It is mainly a diagnosis by means of radiological 
tool. CT Brain is the initial investigation of choice. It may be normal in 30 – 40 
% of the population .MRI with MRV is the gold standard for the diagnosis of 
CVT. D Dimer is a product of fibrinolysis  which is usually used as an 
exclusion marker of venous thrombosis. Our study aims to analyse  the 
usefulness of  D Dimer as an initial diagnostic marker in CVT. 
OBJECTIVES:  
1. To estimate the level of plasma D-DIMER and its significance in diagnosing 
Cerebral Venous  Thrombosis . 
2. To correlate the relationship between plasma D-DIMER and MRI BRAIN in   
diagnosing Cerebral Venous Thrombosis. 
3. To evaluate the diagnostic value of negative D-DIMER in ruling out 
Cerebral Venous Thrombosis.  
METHODOLOGY : 
        The patients diagnosed to have CVT by MRI in Coimbatore Medical 
College above 18 yrs of age are included in the study. A total of 50 patients are 
included in the study. After confirming the diagnosis , blood samples were 
xxv 
 
drawn ,plasma separated and sent to laboratory. D Dimer tests were measured 
by ELISA test. A value of more than 500 ng/ml were considered positive. All 
the tests were entered in a data collection sheet in an Excel format and analysed 
using SPSS software. 
RESULTS :  
    Out of the 50 patients, 28 were females, and 28 were above 35 yrs. The 
common presenting symptom is headache (96%), followed by seizures, altered 
sensorium, with papilledema (60%). The most common sinus involved is 
superior sagittal sinus (70%) followed by sigmoid and transverse sinus. CT 
Brain was normal in 50 % of the patients. Inherited thrombophilias contribute to 
23 %.D Dimer was positive in 78 % of the study population. D Dimer and MRV 
has a highly significant correlation (0.034). D Dimer and onset of symptoms 
have a very high significant value  of 0.000. 
CONCLUSION : 
           D Dimer can be used as an initial diagnostic bio marker in CVT as there 
is a significant association with MRI .If patients present very early D Dimer is a  
highly reliable investigation. Further studies needed for the supportive evidence. 
Key Words: Cerebral Venous Thrombosis, D Dimer ,Magnetic Resonance 
Imaging 
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INTRODUCTION 
        Cerebral venous thrombosis (CVT) is a common  cerebrovascular 
accident due to a multitude of causes. The diagnosis is often missed 
because of its varied clinical presentation. The etiological factors are even 
more heterogenous making cerebral venous thrombosis a unique clinical 
entity .The disease can occur de nova as the first manifestation, or can 
overlap on another co existing clinical problem. The occurrence of 
thrombus depends upon the site, duration, extent and the rapidity with 
which the thrombus occurs. The presentation of CVT is variable in the 
form of convulsions, increased intra cranial tension, meningeal infection 
or hemorrhage.
 
           Although CVT has its varied presentation, headache is the most 
common symptom.
1
 The diagnosis requires a high index of suspicion. CT 
Scan may show direct and indirect signs. At times CT may be normal. 
MRI with MRV is the diagnostic investigation of choice. The early 
diagnosis of this condition will prevent the mortality and morbidity of the 
society as it is treatable condition. 
        Plasma D-Dimer (fibrin degradation product) may be a good 
investigation for the diagnosis of CVT. D Dimer has a very high negative 
predictive value of ruling out venous thrombo embolism in DVT and 
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pulmonary embolism. Several studies been done for analyzing the value 
of D- Dimer in excluding cerebral venous thrombosis. This study aims to 
evaluate the usefulness of plasma D-Dimer  as an initial diagnostic 
biomarker for the diagnosis of cerebral venous thrombosis. 
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OBJECTIVES 
1. To estimate the level of plasma D-DIMER and its significance in 
diagnosing Cerebral  Venous  Thrombosis . 
2. To correlate the relationship between plasma D-DIMER and MRI 
BRAIN in diagnosing  Cerebral Venous Thrombosis. 
3. To evaluate the diagnostic value of  negative  D-DIMER in ruling out 
Cerebral Venous Thrombosis. 
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REVIEW OF LITERATURE 
HISTORY : 
          The syndrome of cerebral venous thrombosis was recognized in the 
early part of 18
th
  century. Ribes was the first to demonstrate the evidence 
of cerebral venous thrombosis in 1825.
2
 John Abercombie of Scotland 
described this entity in a 24 yr female in 1828.
3
 Autopsy showed features 
suggestive of ischemic and hemorrhagic infarct with thrombosed and  
sclerosed veins. With the advent of three dimensional flow imaging 
modalities, the prevalence of CVT is more common than reported 
previously and by early intervention morbidity and mortality has been 
reduced drastically. 
EPIDEMIOLOGY :  
          Cerebral venous sinus thrombosis is rare. The incidence in adults is 
around 3- 4 cases per million. The major occurrence is in 3 rd decade, out 
of which females is around 75 %.
4 
The use of oral contraceptive pills is 
the main reason for the disparity between the difference between males 
and females. It is more common in the middle east countries, because of 
the presence of Behcet’s disease. The incidence of CVT in the west is 3-4 
million, in developing countries it is 4.5 /10000 obstetric admission .
5 
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ANATOMY OF  CEREBRAL VENOUS SYSTEM :
6,7 
     Cerebral venous circulation exhibits following anatomical 
characteristics  
• Cerebral veins have specific feature that it lacks neither any valves 
nor tunica muscularis .The blood flow occurs in various directions 
because of the absence of valves. The  dilatation of veins is mainly 
because of the tunica muscularis. 
• There are several inter communications between the cerebral veins, 
and because of this only the recovery is either complete or with 
minimal residual disability 
• Venous sinuses are enclosed  between the two  layers of duramater. 
This is the reason why cerebral veins are not compressed during 
raised intra cranial pressure  
• There are several emissary veins draining  into cerebral veins either 
directly or via venous lacunae. The emissary veins include from the 
scalp, face, paranasal sinuses, ears, diploic veins and meningeal 
veins. This is the reason behind the presence of CVT  which occurs 
as a complication of infective pathology in catchment areas. 
• The superior sagittal sinus receives blood from superficial cortical 
veins. The flow is in the opposite direction as that of the sinus thus 
causing a turbulent blood flow which is also increased  by the 
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presence of fibrous septations at the inferior angle of the sinus. 
This is why superior sagittal sinus is the most common sinus 
involved in CVT . 
• Arachnoid  villi drain CSF into the superior sagittal sinus .The 
occurrence of thrombosis in this sinus causes obstruction of the 
CSF flow leading to intracranial hypertension and papilledema . 
• Deep cortical veins forms a venous circle around midbrain, like the 
arterial circle of willis. 
• The cerebral veins  drain  into the dural sinuses, which then drain 
into the two internal jugular veins . 
DURAL VENOUS SINUSES: 
   Cerebral venous system can be classified into two major groups  : 
1. Superficial system – sagittal sinuses, cortical veins draining 
superficial surfaces of both cerebral hemispheres. 
2. Deep system   –   lateral sinus, straight sinus, sigmoid sinus along 
with draining deep cortical veins.                      
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Figure 1: Anatomy of Cerebral Venous Sinuses 
I. SUPERIOR SAGITTAL SINUS (SSS) :   
o The superior sagittal sinus occupies the upper, attached  
margin of the falx cerebri. It is triangular in cross section.  
o It begins anteriorly at the crista galli by the union of the tiny 
meningeal veins. It communicates with the veins of the 
frontal sinus and occasionally with the veins of the nose, 
through the foramen caecum. 
o  It ends near the internal occipital protruberance by turning 
to one side, usually the right, and  continuous with the right 
transverse sinus. 
11 
 
o The junction of all these sinuses is called confluence of 
sinuses. 
           TRIBUTARIES: 
  Superior cerebral veins 
  Parietal emissary veins 
  Venous lacunae 
Thrombosis of the SSS may be caused by spread of infection from 
the nose, scalp and diploe. This gives rise to rise in intracranial   
tension, delirium, convulsions, paraplegia of UMN type. 
 
                     Figure 2 :  Anatomy of Superior Sagittal Sinus  
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II. INFERIOR SAGITTAL SINUS : 
• The inferior sagittal sinus , a  channel lies in the posterior 
two thirds of the lower, concave  margin of the falx cerebri. 
• It forms the straight sinus by joining with the great cerebral 
veins. 
III. STRAIGHT SINUS : 
• The straight sinus lies in the median plane within the 
junction of falx cerebri and the tentorium cerebelli. 
• The inferior sagittal sinus and the great cerebral vein joins to 
form the straight sinus. It  ends at the internal occipital 
protruberance .It continues  as the transverse sinus .  
• At the termination of the great cerebral veins into the sinus, 
there exists a ball valve mechanism , formed by a sinusoidal 
plexus of blood vessels ,which regulates the secretion of 
CSF. 
IV. TRANSVERSE SINUS : 
• They  are  large sinuses.. 
• The right sinus usually bigger  than the left situated in the 
posterior part of the attached margin of the tentorium 
cerebelli. 
13 
 
• The superior saggital sinus continues as the right transverse 
sinus. 
• The straight sinus continues as the left transverse sinus. 
• Each sinus extends from the internal occipital protruberance 
to the postero inferior  angle of the parietal bone at the base 
of the mastoid process where it bends and becomes the 
sigmoid sinus. 
V. SIGMOID SINUS : 
• The transverse sinus continues as the sigmoid sinus. 
• It is S shaped. It extends from the  parietal bone to the 
posterior part of the jugular foramen . 
• It grooves the mastoid  part of the temporal bone . 
VI. CAVERNOUS SINUS : 
• Each cavernous sinus is a large venous space situated in the 
middle cranial fossa . 
• It lies on either side of the sphenoid bone. 
• Its interior is divided into a number of spaces or caverns by 
trabeculae. 
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STRUCTURES IN THE LATERAL WALL OF CAVERNOUS 
SINUS FROM ABOVE DOWNWARDS : 
• Oculomotor nerve  
• Trochlear nerve 
• Ophthalmic nerve  
• Maxillary nerve  
 STRUCTURES PASSING THROUGH THE CENTRE OF THE 
SINUS : 
• Internal carotid artery  
• Abducent nerve 
                
Figure 3 : Anatomy of Cavernous Sinus  
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VII. OTHER SINUSES : 
• Occipital sinus 
• Spheno parietal sinus  
• Superior petrosal sinus  
• Inferior petrosal sinus  
• Basilar plexus of veins 
• Petro squamous sinus 
• Anterior and posterior intercavernous sinus  
GROUPS OF VEINS : 
• EXTERNAL CEREBRAL VEINS : 
1. SUPERIOR CEREBRAL VEINS :  
• These are 6 – 1 2 in number. 
• The superolateral surface of the brain is drained by this vein.  
• They terminate in the superior sagittal sinus.  
2. SUPERFICIAL MIDDLE CEREBRAL VEIN : 
• This drains the area around the posterior ramus of lateral 
sulcus. 
• It terminates in the cavernous sinus. 
• It communicates with the superior sagittal , transverse 
sinuses and the deep middle cerebral veins. 
16 
 
 
3. DEEP MIDDLE CEREBRAL VEIN : 
• The area of insula is drained by this vein. 
• It ends in the basal vein. 
 
4. INFERIOR CEREBRAL VEINS : 
• They are divided  into  2 veins , orbital and tentorial veins. 
• The orbital veins terminate in the superior cerebral veins or 
in the posterior sagittal sinus. 
• The tentorial sinus terminate in the cavernous or any other 
surrounding sinus. 
5. ANTERIOR CEREBRAL VEINS  : 
• The corpus callosum and the medial surface of cerebral 
hemisphere is drained by these veins and they ends  in the 
basal vein . 
• INTERNAL CEREBRAL VEINS : 
• There is one vein on each side . 
• It is formed by the union of the thalamostriate and chordal 
veins at the apex of the tela choroidea of the third ventricle . 
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• The right and left veins run posteriorly parallel to each other 
in the tela choroidea and unite together to form the great 
cerebral vein below the splenium of the corpus callosum . 
• TERMINAL VEINS : 
1. GREAT CEREBRAL VEIN : 
• This is a single median vein. The two internal cerebral veins joined 
to form the great cerebral vein. It terminates in the straight sinus. 
   2. BASAL VEIN : 
• There is one vein on each side . It is formed at the anterior 
perforated substance by the union of the deep middle cerebral 
veins, and the striate veins. It runs posteriorly  and terminates 
by joining the great cerebral vein 
• Ultimately all veins empty  into the various cranial   venous  
sinuses which in turn drain into the internal jugular vein.   
Figure  4 : Anatomy of cerebral veins 
 
PATHOGENESIS: 
         The most commonly involved 
sinus, lateral sinus (transverse sinus , sigmoid si
sinus.  The least  frequently affected sinus
of Gallen. The smaller cortical veins may be affected by thrombus even 
without involving the major sinuses .Th
misdiagnosis in computed tomography and magnetic resonance imaging .
               The occlusion of the sinuses  may be due to the
partial thrombus or by the complete occlusion produced by the extrinsic 
compression. The thrombus may extend to the cerebral  cortical
18 
 
 sinuses are the superior 
nus ) and cavernous 
 are straight sinus and the vein 
is is one reason for the 
 formation of 
 
 saggital      
 
 veins, 
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once the thrombus is blocked by the  thrombus. The complete occlusion 
of the sinus by the thrombus results in cortical venous infarct .
8
 
 
 
 
        
Figure 5 : Pathogenesis of Thrombosis – Virchow’s Triad 
8,
  
          The occurrence of intracranial hypertension is most common in 
venous thrombosis.
1
 The main pathology is the development of 
intracellular swelling which occurs due to ischemia produced by the 
occlusion. This ischemia damages the cellular membrane pumps which 
are energy dependent. The disruption in the blood brain barrier and the 
leakage of plasma into the interstitial space causes vasogenic edema . If 
the underlying cause  is treated promptly  it is reversible. There will be 
defect in the absorption of CSF leading to increased intracranial tension 
because of the occluded sinus by the thrombus.
1
 Thrombosis of the 
20 
 
venous sinuses leads to impaired absorption of  CSF and consequently 
increased intracranial hypertension  
 
Figure 6: Pathogenesis of CVT 
Various theories have been postulated for the pathogenesis of cerebral 
venous thrombosis. The main factors incriminated are  
    1. Infective theory 
    2. Embolism 
    3. Local endothelial damage 
    4. Hypercoagulability 
                                  
Figure 
 
PATHOLOGY : 
    The pathological findings are determined by 
• Underlying disease pathology 
• Nature of sinus/cerebral vein involved 
• Interval between the onset and pathological examination 
21 
7: Pathology and Etiology 
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  Cortical vein thrombosis usually presents as a cord like swelling 
with minimal or absent hemorrhagic infarction of the brain. This has 
been explained based on the intercommunications between various 
cortical veins and sinuses. Cortical veins are also swollen and may 
rupture at some place giving rise to hemorrhagic infarction  and even 
intracerebral hemorrhage .Microscopy shows typical changes of 
hemorrhage, but specific features appears to be profuse leukocytic 
invasion because of patent arteries allowing  inflow of inflammatory 
cells. 
9 
         
                                                        
 
 
 
Figure 8: Pathology of Hemorrhagic Infarct 
AETIOLOGY :  
              Venous thrombosis anywhere in the body results from increased  
activity of mechanism of  hemostasis  or decreased  activity of one or 
more anti thrombotic mechanisms or a combination of both. The liquid 
state  of blood is maintained by normal intact endothelium, prostacyclin, 
23 
 
anti thrombin III , heparin sulphate, thrombomodulin , protein C & S, 
fibrinolytic system, normal flow of blood and the absence of 
hypercoagulable state. Several causes has been documented as the cause 
of CVT. Even with elaborate investigations 20 – 25 % of causes no 
etiology has been found.
10 
CAUSES OF CVT  :  
 
 TABLE 1 : SEPTIC DURAL SINUS THROMBOSIS  
 
S.NO LOCAL SYSTEMIC 
1. Septic Trauma BACTERIA- Typhoid,  
TB, Septicemia, 
Endocarditis 
2. Infection,  Meningitis, 
Abscess 
VIRUS – Measles, 
Hepatitis, Herpes , HIV 
3. Sinusitis PARASITE – Malaria, 
Trichinosis 
4. Tonsillitis FUNGUS – Aspergillosis  
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TABLE 2 : NON SEPTIC DURAL SINUS THROMBOSIS : 
HEMODYNAMIC STATES  
• Dehydration 
• Fever 
• Cardiac failure 
HEMATOLOGICAL DISORDERS   
• Polycythemia 
• DIC 
• Sickle cell anemia  
• Severe anemia 
• PNH 
• Thrombocytosis 
• APLA 
• Anti thrombin III deficiency 
• Protein C deficiency 
• Protein S deficiency 
• Homocysteinemia 
• Dysfibrinogenemia 
• Factor V Leiden mutation  
HORMONAL DYSFUNCTION 
• OCP 
• Pregnancy 
• Androgen 
TRAUMA  
• Head injury 
• Surgery 
• Cardiac pacemaker 
METABOLIC DISORDERS 
• Homocystinuria 
• Diabetes mellitus  
• Osteopetrosis 
NEOPLASM  
• Meningioma 
• Metastasis 
INFLAMMATORY DISORDERS  
• Behcet’s disease    
• Sarcoidosis 
• SLE , PAN ,Wegener’s 
 
VASCULAR DISORDERS  
• Arterio venous occlusions 
• Sturge weber syndrome 
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I. PROTHROMBOTIC CAUSES OF CVT : 
     Thrombophilia is a constellation  of symptoms with  predisposition to 
form clots inappropriately. Now ,it has been recognized that congenital 
thrombophilia and prothrombotic states are the most common non 
infective causes of CVT.
11 
The predisposition to form clots  arise because of an association  between 
genetic and acquired factors.
12
 Inherited thrombophilias account for 22.4 
%
12
 of  CVT cases . 
In patients with age < 45 yrs  ,with a family history of venous thrombosis 
and who has no apparent risk factors presented with recurrent CVT, 
inherited thrombophilia should be thought of .The risk of CVT is more in 
patients with inherited thrombophilia with the presence of other risk 
factors for CVT .
13 
The mechanism underlying venous thrombosis include 
decreased neutralization of thrombi in patients with anti thrombin 
deficiency and reduction in the control of thrombin generation in  patients 
with Factor V  Leiden mutation, prothrombin gene mutation and protein 
C & S deficiency.
13 
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II. TABLE 3 :GENETIC CAUSES OF CVT :
14
 
Disorder Gene Inheritance General 
population 
With CVT 
(%) 
Activated Protein 
C Resistance 
Factor v 
Leiden 
mutation 
AR 2- 15 % 5- 20 
Prothrombin 
20210 
Prothrombin AR 0.1 1- 5 
Protein C 
deficiency 
Protein C 
gene 
AR 0.2 – 0.4 3- 6 
Protein S 
deficiency 
Protein S 
gene 
AR 0.03 – 0.13 1-5 
Factor VIII 
elevation 
Von 
Willebrand 
factor 
deficiency 
AR 10 25 
Antithrombin III 
deficiency 
Anti 
thrombin III 
AR RARE 3--8 
Plasminogen 
deficiency 
Plasminogen 
activator 1 
AR   
 
The common hereditary thrombophilic states predisposing to CVT are 
described below: 
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(a)   FACTOR  V LEIDEN MUTATION : 
     There is a defect in the Factor V gene , with less susceptibility to 
inactivation by activated protein C .
15
 Factor V a is sequentially cleaved 
at Arg 506 and Arg679 by activated protein c is demonstrated  in 1995.
16
 
They demonstrated that the peptide bond cleavage at Arg506 facilitates 
the exposure of the subsequent cleavage sites at Arg306 and Arg679. The 
inactivation of factor VIII a by APC is mediated by the Factor V.
17
 The 
transition  results in the replacement of arginine by glutamine. This  is 
called as Factor V leiden ,also known as factor v Q506 or Arg 506 
Gln.Factor V is  a variant of a normal gene.The activated protein C will 
not be helpful in cleaving the Factor V .This leads to the production of 
increased Factor V within the prothrombinase complex ,producing a 
hypercoagulable state and increased thrombin generation.
18 
(b) PROTHROMBIN GENE MUTATION : 
               This mutation was first described in 1996 by Poort . Thrombin 
is the end product of coagulation cascade which is formed by 
prothrombin. Prothrombin has 3 main activities related to coagulation 
which includes procoagulant,anticoagulant and anti fibrinolytic 
activities.Because of these varied properties, a disorder involving the 
prothrombin complex results in hemostasis disorder.
19
This gene mutation 
has a wide variable geographic distribution. 
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(c) PROTEIN C DEFICIENCY : 
                It is an autosomal dominant condition. It is most commonly  
associated with familial venous thrombosis.The chromosome 2 is the 
gene for protein C , which is  related to the factor IX gene .
20
The 
heterozygous protein C deficiency is of two types.(Type I and Type II). 
21 
 TYPE I Deficiency : 
• It is more common. 
•  Most of them  are heterozygous . 
• They have a reduced plasma protein C concentration  
• Majority of the mutations are missense and non sense 
mutations. 
 TYPE II DEFICIENCY :  
• They  have normal plasma Protein C antigen levels with 
decreased functional activity.
18
 
             The presence of protein C deficiency confers a high  risk of 
venous thrombosis. More than 60 %  of patients had  recurrent venous 
thrombosis and about 40 % have features of pulmonary embolism.
22 
(d) PROTEIN S DEFICIENCY : 
              It was originally discovered  and purified in Seattle, leading to 
the designation Protein S. There are two homologous genes for protein S : 
29 
 
PROS 1 and PROS 2. They have been mapped to the chromosome 3.
23 
Based on total protein S antigen concentration, free protein S 
concentration and protein S functional activity, three phenotypes of 
protein S deficiency have been documented. 
 TYPE I PROTEIN S DEFICIENCY :    
• This is the classical type . 
• This is associated with decreased level of total S antigen, 
marked decrease in free protein S antigen and protein S 
functional activity.
24
 
 TYPE II PROTEIN S DEFICIENCY :  
• There is  normal total and free protein S levels, but  protein S 
functional activity is reduced .
25
 
 TYPE III PROTEIN S DEFICIENCY : 
• This is characterized by normal protein S antigen,decreased 
free protein S  and its functional activity .
26
 
              The clinical manifestations are similar to those seen with protein 
C and antithrombin deficiency. The  probability of acquiring thrombosis 
is increased 9 times higher compared to controls. 
(e) DYSFIBRINOGENEMIA :   
           The dysfibrinogenemia  occurs because of the defect in the 
production of fibrinogen. The binding between TPA and fibrin 
30 
 
remains normal.
27 
The activation of plasminogen with fibrin is 
mediated by fibrin, and this is reduced with the abnormal type known 
as fibrinogen Dusard. It has an autosomal dominant  pattern of 
inheritance. Most of the patients are asymptomatic. Some of the 
patients present with features of bleeding diathesis, thrombophilia or a 
combination of both.
18
The occurrence of venous thrombosis in 
congenital dysfibrinogenemia is estimated to be 0.8%. 
(f) ELEVATED FACTOR VIII: 
               The risk of venous thrombosis is increased in patients with 
increased levels of factor VIII.
28,29,30
 This accounts for about 20 % of 
patients with venous thrombosis. In addition, normally 10 % of patients 
had increased factor VIII level. The mechanism of thrombosis in 
condition is not clear. It has been postulated as an independent risk factor 
for recurrent venous thrombosis. False positive results can occur in 
pregnancy, inflammation, trauma and renal diseases. However in patients 
with thrombosis the elevated levels will persist for a longer duration of 
time. This test should be taken as a part of routine examination in patients 
with suspected thrombophilia , as this has an increased risk of venous 
thrombosis.
31 
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(g) HYPERHOMOCYSTEINEMIA:   
                 Hyperhomocysteinemia  can occur both as a congenital or as 
an acquired abnormality. Homocysteine is an amino acid which is  a by 
product of methionine. Homocysteine is metabolized in the body by 
transsulfuration and remethylation. The  cysteine   is produced by the 
trans sulfuration of homocysteine and the reaction is catalysed by 
cystathinonie beta synthase. The cofactor needed in this reaction is 
pyridoxal phosphate. Methionine is produced by the remethylation of 
homocysteine  and  is catalysed by methionine synthase. Vitamin B12 is a 
cofactor for methionine synthase. Elevated levels of plasma 
homocysteine can thus occur because of enzymatic defect or due to 
nutritional deficiencies .The most common mutation associated with 
genetic hyperhomocysteinemia results from the production of 
thermolabile variant of methylene tetrahydrofolate reductase with 
reduced enzymatic activity. This is the most specific and strong risk 
factor for CVT.
32,33,34 
(h) ANTI PHOSPHOLIPID ANTIBODY SYNROME (APLA ): 
         Antiphospholipid antibodies are acquired serum immunoglobulins. 
The anticardiolipin antibodies and lupus anticoagulant are the most 
frequently studied antibodies. It is an important cause of systemic arterial 
and venous thrombosis. The presence of anticardiolipin antibodies poses 
32 
 
an increased risk of CVT at an early age group and they have an more 
extensive involvement of sinuses
35
 and they carry a more frequent risk of 
thrombosis. This entity has been identified as an important cause of 
acquired thrombophilic defect.
36 
PREGNANCY AND CVT : 
• Pregnancy and postpartum period are the important period in 
occurrence of CVT . 
• Pregnancy itself is a hypercoagulable state because of the 
changes in the blood composition  
• Obesity , caesarean section , immobilization is also a 
contributing factor for CVT in pregnancy. 
• Hyperhomocysteinemia is an associated co factor in 
pregnancy because of malnutrition and folic acid deficiency. 
• Frequency of  peri/postpartum  CVT is 12/100000 deliveries  
     CONTRIBUTORS OF THROMBOSIS IN PREGNANCY  
• Release of thromboplastin from placenta into circulation 
• Ischemia during delivery of fetus 
• Reactive thrombocytosis due to hemorrhage 
• Iron deficiency 
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CLINICAL FEATURES: 
• The clinical presentation of CVT is varied, depending upon 
the site, extent and the rate of thrombosis.  
• There is a slight female preponderance .
37
 
• Usual onset is in 3 rd or 4 th decade
38
 
• The superior sagittal sinus
39
 and lateral sinus are more 
commonly involved than the deep venous system.  
• If the symptoms are restricted to dural sinuses it will manifest 
with features suggestive of raised intracranial hypertension  
• If the cortical veins are involved , focal deficits and seizures 
may be the presenting features .
40
 
FACTORS DETERMINING THE CLINICAL PROFILE OF CVT : 
• Underlying sinus/venous system involved  
• Mode of onset – acute,subacute or chronic 
• Time interval between onset and presentation  
• Nature of primary disease giving rise to CVT
41
  
SYMPTOMS  AND SIGNS : There are varied  mechanisms for the 
development for signs and symptoms of CVT . 
1. Venous obstruction, ischemia ,infarction or hemorrhage and the 
neuronal dysfunction . 
34 
 
2. The compressive effect  of a mass  
3. Venous obstruction leading to sudden increased intra cranial 
tension  
4. Hyperexcitability  with  neuronal dysfunction due to the 
underlying etiology responsible for a thrombophilic state. 
i. HEADACHE : 
        Headache is the most common presenting symptom .It is the 
manifestation in 70 – 80 %
42
 of the patients. It may present as a very 
acute, severe presentation
43
 like thunderclap headache or it may present 
as subacute or chronic. Usually it is not decreased by taking rest .It 
increase gradually over a few days. It may be associated with nausea, 
vomiting and other features of raised  intra cranial hypertension .It mainly 
occurs because of leakage of blood to the surface which stimulates pain 
sensitive fibres in the dura or due to rise of intracranial pressure. 
ii. FEVER :  
        It occurs in 15 – 60 % of cases. This is often present with septic 
CVT or those secondary to systemic infection 
44
.Superior saggital sinus 
thrombosis in infants and children may present only with fever and 
convulsions which may mimic febrile seizures .  
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iii. SEIZURES : 
     Seizures are more common in patients presenting with focal 
neurological deficits. 40  % of patients present with seizures of which it is 
focal in 50 % of the cases 
45
. Seizures may be focal, multifocal or 
generalized .It occurs commonly due to irritation of the cortex because of 
the hemorrhagic venous infarct. Seizures are the most common 
manifestation in venous infarct than in arterial stroke . 
iv. FOCAL DEFICITS AND ALTERED SENSORIUM  : 
   Focal signs vary with extent and site of thrombosis. They may be motor 
or sensory, unilateral or bilateral .It occurs in approximately 60 % of 
patients. Thrombosis of the deep venous system produces features of  
delirium, amnesia, mutism. If the infarct is big enough to cause 
compressive symptoms patient will be in coma because of herniation. 
       Altered sensorium is usually due to raised intracranial pressure and is 
often preceded by headache and severe focal deficits. 
v. CRANIAL NERVE SYNDROMES : 
        They are most commonly seen with lateral venous sinus thrombosis. 
These include features suggestive of 6,7,8 cranial nerve involvement . If 
the thrombus in the lateral sinus extends to the jugular veins ,
46,47
 the 
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patient have features suggestive of lower cranial nerve involvement 
involving IX , X, XI ,XII . 
vi. PAPILLOEDEMA : 
The incidence of papilloedema is variable  and depends on the etiology, 
rate and site of venous thrombosis. It is less common in puerperal CVT. 
Severe papilloedema can cause transient as well as permanent visual loss. 
The underlying mechanism is due to an increase in venous pressure 
secondary to thrombosis of the of the dural venous sinuses, which alters 
the pressure gradient resulting in poor  CSF absorption through the 
granulations 
47 
 
 
 
 
 
 
Figure 9: Fundus picture of papilloedema 
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vii. OTHER PRESENTATIONS :  
        These are uncommon and include signs of meningeal irritation , 
cortical blindness, akinetic mutism , dystonia, attacks of migraine with 
aura ,psychiatric disturbances , etc..
44,47 
 
      GRAPH 1 : FREQUENCY OF CLINICAL MANIFESTATIONS  
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PATTERNS OF PRESENTATION : 
      There are 4 main clinical presentations of CVT  
1. FOCAL DEFICITS / PARTIAL SEIZURES :  
It is characterized by  seizures, headache, altered sensorium, focal 
deficits. It   may also manifest as isolated seizures. 
2. ISOLATED INTRACRANIAL HYPERTENSION : 
    This comprises headache , nausea,vomiting , papilledema, nerve palsy. 
3. SUBACUTE DIFFUSE ENCEPHALOPATHY : 
This is characterized by a decreased level of consciousness without 
ICT features. 
4. PAINFUL OPHTHALMOPLEGIA :This is caused by lesions of the 
3 ,4 ,6  cranial nerves, chemosis and proptosis in patients with 
cavernous sinus thrombosis .
48
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PATTERNS OF 
PRESENTATION
                      
Figure 10: Patterns of presentation of CVT 
RELATIONSHIP BETWEEN CLINICAL MANIFESTATIONS 
AND THE SITE OF OCCLUSION : 
• Occlusion of cortical veins – motor/ sensory deficits, seizures or 
both 
• Occlusion of sagittal sinus -  motor deficits, seizures  
• Occlusion of lateral sinus – isolated intracranial hypertension 
syndrome  
40 
 
• Occlusion of deep cerebral veins – severe coma, delirium , 
bilateral motor deficits  
• Occlusion of cavernous sinus – orbital pain , chemosis, proptosis , 
occulomotor palsies 
49
 
           
•  
Figure 11:  sinuses and their clinical features 
INVESTIGATIONS : 
NEURO IMAGING OF THE THROMBOSED VESSEL : 
                 The diagnosis of  CVT is  mainly based on imaging modalities. 
It usually shows non specific lesions . Moreover , neuroimaging may be 
normal in 25 – 30 % of the patients with CVT . CVT is identified by the 
imaging of the venous circulation which identifies the thrombus in the 
41 
 
occluded  vessel. The current gold standard test for the diagnosis of CVT 
is MRI with MRV
50
. The neuroimaging methods commonly used to 
describe CVT are described below  
(A)   COMPUTED TOMOGRAPHY (CT BRAIN ) : 
 Conventional CT is the best non invasive investigation of choice for 
identifying CVT.  CT may be normal in 25 – 30 % of the patients with 
isolated intracranial hypertension
50
 .However CT BRAIN is the initial 
investigation  in the emergency  room  not only to find out CVT but also 
to rule out other causes which may mimic CVT .The diagnostic value of 
CT may be increased, when it is combined with helical CT venography .
51 
 The infarction in the non arterial distribution with hemorrhage implies 
the possibility of CVT. 
 
 
                         
 
 
 
Figure 12: CT Brain showing hemorrhagic infarct 
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The CT findings of CVT may be as follows 
• CORD SIGN : This is seen  in plain  CT scans. It represents the 
visualization of a thrombosed cortical veins spontaneously without 
any contrast. It is not very reliable as it can be also seen in internal 
cerebral vein thrombosis. 
• DENSE TRIANGLE SIGN : It represents spontaneous superior 
sagittal sinus obscuration  by freshly coagulated blood. It is present 
in only less than 2 % of cases. 
 
                       
 
 
 
 
 
Figure 13 :  CT Brain showing dense triangle sign 
 
43 
 
• EMPTY DELTA SIGN : It is seen in contrast enhanced CT 
and it was first described by Buonanno and colleagues. It 
reflects the contrast between the opacified and  the non 
opacification of the clot inside the sinus. The most common 
direct sign in CVT is empty delta sign and it is demonstrated in 
approximately 28- 72 % % of the cases.  
 
                    
 
 
 
 
 
 
Figure 14: CT Brain demonstrating Empty delta sign 
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ABSENCE OF EMPTY DELTA SIGN : 
• When posterior third of superior saggital sinus is not 
involved  in thrombosis. 
• CT scan is done either early or very late after the onset of 
symptoms. 
INDIRECT SIGNS OF CEREBRAL VENOUS THROMBOSIS : 
• Approximately 20 % of cases will demonstrate intense contrast 
enhancement of the falx and tentorium. Superior saggital sinus 
thrombosis is usually demonstrated by tentorial enhancement. 
There may be  dilated transcerebral medullary veins, implying  a 
major venous stasis, indicating a large SSS thrombosis. 
• cerebral edema is characterized by white matter hypodensity  
without any enhancement..It is seen in upto 75 % of patients. 
• Hemorrhagic  venous infarct – in 10 – 50 % of the patients .There 
is an associated sub arachnoid hemorrhage or a subdural hematoma 
in rare instances. It can only present as the only sign of CVT.  
• Non hemorrhagic venous infarct – the incidence is almost equal to 
that of hemorrhagic venous infarct. They  may be seen in the 
hemispheres or in the basal ganglia..
52
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Figure 15:   CT Brain showing massive hemorrhagic infarct 
NORMAL CT SCAN  -  CVT :  
      In 20 – 30 % of patients with CVT ,CT may be normal. In patients 
with isolated intracranial hypertension it may be normal in 50 % of cases 
53
. The main aim of CT  is rule out the other conditions mimicking CVT. 
Very few CT shows the classical domain of CVT . MRI /MRV is the 
diagnostic modality preferred nowadays. 
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(B)    MAGNETIC RESONANCE IMAGING  : 
         MRI with MRV is the sole diagnostic investigation of choice  for 
CVT
39
 .The clot can be directly visualized in the sinus with the help of 
MRI .The clot has a varied picture depending upon the duration of 
thrombosis. The thrombosed vessel appears isointense on T1 MRI and 
hypointense on T2 image in the very early stages of formation of 
thrombus. This phenomenon may not be visualized in MRI. This 
difficulty can be overcome by MRV. The flow void becomes absent and 
the thrombus becomes hyperintense, first on T1 and later  on T2 MRI , 
which is mainly due  to the conversion of oxyhemoglobin to 
methemoglobin within the thrombus .It starts about 5 days after and lasts 
nearly for 35 days. The occlusion will be removed or there may be 
recanalisation of the vessels after a certain period, during that period even 
MRI is not diagnostic .The abnormalities may persist for more than 6 
months in about 2/3 rd of patients .
54 
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              Figure 16:  MRI Brain showing transverse  sinus thrombosis 
             MRI is also useful in assessing other associated features apart 
from CVT , which includes cerebral edema or infarct . However false 
negative and false positivity can also occur. 
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                                DWI - LIMITATIONS 
False positive False negative 
• Slow flow of blood without 
thrombus 
• Acute thrombus – early stage 
• Isolated cortial vein 
thrombosis 
• Partial recanalisation 
   
Diffusion weighted imaging – Advantages : 
• Direct visualization of clots 
• Heterogenous signal intensity 
• No diffusion abnormality 
 
 
 
 
 
 
                         
 
 
Figure 17 : MRI  - SIGMOID SINUS THROMBOSIS 
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(C)  MAGNETIC RESONANCE VENOGRAPHY :  
MRV is now the best diagnostic modality of choice at present .There 
are three methods , which are as follows 
• Two dimensional time of flight (TOF ) 
• Three dimensional time of flight  
• Phase contrast  
        The most commonly used method is two dimensional 
flight..The slices will be 1.5 and 3mm.The absence of flow in the 
veins is the typical appearance in CVT in MRV indicating 
complete occlusion of the veins. 
     LIMITATIONS : 
• Difficult to diagnose partial thrombosis 
• Difficult to diagnose hypoplasia and thrombosis
54
 
• Difficulty in detecting cortical vein and cavernous sinus 
thrombosis 
      ADVANTAGE : 
• Easily repeatable  
• Non invasive  
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TABLE 4 :DIFFERENCE BETWEEN CT AND MRI/ MRV 
S.no Characteristics CT brain MRI/ MRV 
1. Visualisation  Major venous sinuses Superficial & deep 
venous system 
2. Time  Not time consuming Time consuming 
3. Radiation  hazard  Present  Absent  
4. With mechanical 
devices  
Can be used Contraindicated 
5. Contrast reactions  Present  Absent 
6. Availability  Easy  Difficult 
7. Accuracy  Good Excellent 
 
 
Figure 18 : MRV of Left Transverse Sinus Thrombosis 
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Figure 19: MRV Showing superior sagittal sinus thrombosis 
(D)   CT HELICAL VENOGRAPHY : 
CT venography can be used as an alternative tool for MRI.
39
 CT 
venography  more or less resembles CT angiography. There will be a 
little delay after giving contrast in order to visualize the venous system 
clearly .The non ionic contrast is injected intravenously at a rate of 3 
ml/sec. From the images obtained bone images are deleted. After that 
images are reconstructed by maximum intensity projection. The images 
of this is closely related to MRI images. Compared to MRV they have 
less artifacts. 
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Figure 20:CT Venography demonstrating the sinuses involved in 
CVT 
ADVANTAGES : 
• 3D CT – reduces the mis interpretation of normal anatomic 
findings which alike CVT 
   DISADVANTAGES : 
• Insufficient time for enhancement 
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(E)   D- DIMER : 
         D- Dimer is a fibrin degradation product .It is a product of 
fibrinolysis. It contains two cross linked D fragments of the fibrin 
proteins and so it is called . The value of the measurement helps to 
predict the presence of thrombosis. The negative D Dimer test always 
rules out the possibility of thromboembolism .
55,56 
The positive test 
implies the presence of thrombus ,but it does not rules out other possible 
causes of elevation.. 
                               
 
 
 
 
 
 
Figure 21 : D Dimer Formation 
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   In the normal human circulation, D Dimers are usually not 
present. It is elevated only when the coagulation cascade is activated .The 
D Dimer assay depends on the interaction between the monoclonal 
antibody and the D Dimer fragment. 
       D-dimer levels are not always uniform. They have a peak value 
during the acute phase of thrombosis. As time goes on the levels of D 
Dimer starts decreasing
57
 .So in patients presenting with subacute or 
chronic symptoms , there will be not much elevation in the level of D 
Dimer. The level of D Dimer correlate with the clot burden. If there is a 
lesser clot burden then the levels wont be much high. At present a variety 
of techniques are  employed  for    determining  D D imer tests. 
      A study conducted in 2004, proves that D Dimer levels was 
abnormal in 34 of 35 patients., giving it a sensitivity of 97.1%, a negative 
predictive value of 99.6%, a specificity of 91.2%, and a positive 
predictive value of 55.7%
58,59
.
 
This study is followed by another study, 
which proves that even with clear cut thrombosis , 10 % of patients had 
normal values of D Dimer. The patients who had only features of isolated 
headache without any other symptoms had normal values of D 
Dimer. The D DIMER levels above 500 ng/ml is
60
 considered to be 
positive for CVT. The method used for estimation is latex slide 
agglutination method. 
55 
 
 
                           
 
 
 
 
 
 
 
Figure 22: D Dimer and CVT  Correlation 
 
TREATMENT : 
          The treatment of CVT is based on assessment of individual cases as 
the spectrum of presentation of CVT is varied .Anticoagulants with low 
molecular weight heparin or dose adjusted intravenous heparin  are  used 
as first line therapy. It is still a question whether to use anticoagulants in 
the acute phase of CVT .
61
 On one hand it can decrease the extension of 
thrombus ,but on the other hand it may worsen the hemorrhage.According 
56 
 
to Martinelli et al ,it is better to delay the initiation of anticoagulation till 
the hemorrhage is stabilized. 
SYMPTOMATIC TREATMENT : 
• The most common cause for CVT is dehydration .In order to treat 
the cause of dehydration use of IV fluids is mandatory. 
• Anticonvulsants for the patients with seizures. There is no clear 
data for the use of prophylactic use of anti convulsants in seizures. 
It is continued for a minimum period of 1- 2 yrs and then 
withdrawn gradually
62
. The withdrawl of anticonvulsants  should  
be based on that the patient had no recurrent seizures , has a normal 
EEG and no neurological sequelae. 
• Measures to reduce increased intracranial hypertension .The 
measures includes steroids, mannitol, glycerol, dextran, 
acetazolamide, lumbar puncture, shunting or even surgical 
decompression .
60
 
• Heparin  therapy 
• There is no role of  steroids in CVT
63
 
• Decompressive hemi craniectomy may be life saving in patients 
with features suggestive of herniation because of mass effect.
64
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ETIOLOGIC TREATMENT : 
The main line of management in CVT is the treatment of the 
underlying etiology behind CVT . The use of wide spectrum of antibiotics 
for treatment of septic CVT and surgical debridement for primary site of 
infection. Malignancies, collagen vascular disorder and hematologic 
disorders need specific treatment. 
 ANTITHROMBOTIC TREATMENT : 
AIMS : 
• Recanalisation of occluded sinus 
• Prevent progression of thrombus 
• Treatment of prothrombotic state 
• Prevention of recurrence 
                    The optimal duration of heparin therapy is uncertain. Once 
symptomatic improvement occurs, heparin is replaced with oral 
anticoagulation. The INR should be maintained within 2-3.The treatment 
should be continued for 6 months if there is no specific prothrombotic 
cause identified . When there is increased risk of further thrombosis like 
that of inherited thrombophilias , treatment should be continued for a long 
time. 
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THROMBOLYTIC THERAPY : 
 If patients deteriorate inspite of adequate anticoagulation, 
thrombolysis may be considered if facilities are available. 
65
 Intravenous 
Urokinase was used in the early 1970’s  for thrombolysis . Now r TPA is 
the most commonly used agent .Both these agents carry the risk of 
hemorrhage. There is no clear cut clinical evidence to show that these 
agents have a better clinical outcome .Angio – jet rheolytic 
thrombectomy is a novel technique. In this method a vacuum is created 
by means of bernoullie effect .This vacuum is used for aspirating the 
thrombus. It can be used for even hemorrhagic CVT, as it has an added 
advantage of lack of hemorrhagic complications.
62
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Figure 23 : Algorithm for management of CVT 
 
Clinical Suspicion of CVT 
 
MRI with MRV 
 
CVT (Confirmed) 
No  evidence of 
CVT consider 
other differential 
diagnosis 
Initiate anticoagulation (IV heparin or SC LMWH) 
 
Neurological Improvement 
 
Neurological deterioration 
Continue oral 
anticoagulation for 3 to 12 
months or lifelong according 
to the underlying etiology 
Severe mass effect 
or ICH on  
repeated imaging 
No or mild mass 
effect on repeated 
imaging 
May consider 
decompressive 
hemicraniectomy 
(lifesaving 
procedure ) 
May consider 
endovascular  
therapy (with or 
without mechanical 
disruption) 
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PROGNOSIS : 
SHORT TERM OUTCOME : 
        The cause of death in CVT are  
1. Large hemorrhagic infarct 
2. Complications like sepsis, uncontrolled seizures, pulmonary 
embolism 
3. Carcinoma, septicemia, leukemia and PNH  
    FACTORS SUGGESTING BAD PROGNOSIS : 
 Rapid progression  of thrombus  
 Patient’s age  
 Infection  
 Focal symptoms and coma 
 Hemorrhagic infarct  
 Empty delta sign on  CT scan 
 Type of veins involved  
FUNCTIONAL RECOVERY : 
The prognosis is better for venous infarct than the arterial infarct. 
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LONG TERM OUTCOME : 
During the initial episode of CVT ,if patient had seizures ,the 
possibility of having residual epilepsy is around 10 – 30 %. 
If the cause of CVT is a hypercoagulable state, there is a possibility 
of recurrence of venous thrombosis. But because of long term 
anticoagulation it is generally uncommon. 
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                                     METHODOLOGY  
SOURCE OF STUDY  :  Patients diagnosed to have Cerebral  
venous thrombosis at Coimbatore 
Medical college. 
DESIGN OF STUDY :  Cross sectional Study 
PERIOD OF STUDY :  AUGUST 2013 – JULY  2014 
SAMPLE SIZE   :  50 
INCLUSION CRITERIA: 
• Patients who are diagnosed to have cerebral venous thrombosis by 
means of MRI and MRV  in Coimbatore medical college within 30 
days of symptoms onset, not started on anticoagulation. 
• Age above 18 yrs. 
EXCLUSION CRITERIA:  
• Pregnancy 
• Puerperium upto 4 weeks 
• Arterial stroke within past  3 months 
• Pulmonary embolism or Deep vein thrombosis 
• Head injury within past 3 months 
• Rheumatoid Arthritis 
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• Intra cerebral mass lesion 
METHODOLOGY: 
              The patients diagnosed to have cerebral venous thrombosis 
confirmed with  MRI BRAIN during the study period  were included. 
After getting informed written consent,careful medical history was 
obtained including clinical features, precipitating risk factors, family 
history .All patients were subjected to meticulous general and 
neurological examination .Patients were subjected to MRI BRAIN with 
Venography on a 1.5 Tesla machine. 
          After confirming the diagnosis of CVT by MRI and MRV  ,blood 
samples were drawn ,plasma was separated, frozen at -80 C and sent to 
the laboratory. A basic hematological work up including complete blood 
counts, peripheral blood smear, ESR, PT/APTT were done. D-Dimer tests 
were measured by using a conventional ELISA Test. A value of more 
than 5oo ng/ml were considered positive tests. In order to find out the 
etiology of CVT , dsDNA,  APLA, serum homocysteine  was done . 
STATISTICAL ANALYSIS : 
  All the dates were entered in a data collection sheet in an Excel 
format and analysed using SPSS Software. Numerical values were 
reported using mean and standard deviation or median. categorical values 
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are reported using number and percentages. probability value (p) value 
less than 0.05 was considered a statistically significant. 
 
 
 
OBSERVATION AND RESULTS
             During the 12 month study period , a total of 50 patients were 
studied for finding out the usefulness of D DIMER as an initial diagnostic 
bio marker in CVT. 
SEX DISTRIBUTION :
Table  5:  Sex distribution among 
SEX 
Female
Male 
Total 
 
GRAPH 2–
 
       Among the 50 patients , 28 were females ( 56%) and 22 were males 
(44%).  The ratio of female: male was 1.3:1.
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the study population
Frequency Percent (%) 
 28 56.0 
22 44.0 
50 100.0 
 Sex Distribution among the population
 
56%
44%
Gender Distribution
Female Male
 
 
AGE DISTRIBUTION:
Table  6: Age distribution among the study population
AGE GROUP
Above 35 yrs
Upto 35 yrs
Total 
 
                            
                            Graph 
 
 
 
 
 
 
 The  age of the patients comes under 2 categories . The majority of them 
are above 35 yrs ( 56 %) .The patients below 35 yrs are around 44 % .
SOCIOECONOMIC STATUS :
low socioeconomic status (64.4%) , the rest belonge
socioeconomic status.
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 Frequency Percentage (%)
 28 56.0 
 22 44.0 
50 100.0 
3 :Age wise distribution of cases  
 Majority of the cases were within the 
d to the middle 
 
Age >35 -
56%
Age <35 -
44%
Age range
 
 
 
SYMPTOMATOLOGY AND SIGNS:
Table 
HEADACHE
NO 
YES
TOTAL
Graph 
      Among the 50 patients , 48 patients  ( 96 %) 
Remaining 2 patients ( 4 % ) didn’t have headache
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7:  Clinical Profile of Headache 
 FREQUENCY % 
2 4.0 
 48 96.0 
 50 100.0 
 
4 : Distribution of Headache 
were having headache .
. 
 
NO YES
HEADACHE
 
 
Table 
 
Graph  
Among the 50 patients , 33 patients (66 %)  didn’t have convulsions ,and 
the remaining 17 patients (34 %)  had convulsions 
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8: Clinical Profile of Convulsions  
 
 
5: Distribution of Convulsions 
 
 
 
NO YES
CONVULSION
 FREQUENCY            % 
33 66.0 
17 34.0 
 50 100.0 
Table 
VOMITING
NO 
YES 
TOTAL 
Graph 
In our study, 31 patients ( 62 
patients(38%) did  not have vomiting.
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9:    Clinical Profile of Vomiting 
 FREQUENCY % 
19 38.0 
31 62.00 
50 100.0 
 
 
6: Clinical Profile of Vomiting  
%)  of CVT had vomiting  and 19 
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 Table 10:  Clinical Profile of Loss of Consciousness
LOC
NO
YES
TOTAL
 
Graph  7: Clinical Profile of Loss of Consciousness
The patients that  presented with loss of consciousness in our study are 13 
( 26 %) , and the remaining  37  patients  ( 74 ) did not have  loss of 
consciousness . 
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 FREQUENCY % 
 37 74.0 
 13 26.0 
 50 100.0 
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Table 11: Clinical Profile o
CRANIAL NERVE
NO
YES
TOTAL
   
             Graph 8: Graph Showing Cranial Nerve
 
 
Among the 50 patients , 11 patients (22%) had cranial nerve involvement 
, and the remaining 39 (78%) 
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f Cranial Nerve involvement
 FREQUENCY %
 39 78.0
 11 22.0
 50 100.0
 involvement 
 had  no cranial nerve involvement .
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FEVER
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In our study population , 36 patients (72 %) had no fever and
remaining 14 ( 28 %) patients had fever.
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Table 12: Profile of Fever 
 FREQUENCY % 
36 72.00 
14 28.00 
 50 100.0 
Graph 9: Profile of Fever 
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                             Table 
PAPILLEDEMA
NO
YES
TOTAL
 
Graph 10: Spectrum of
    Among the 50 patients , 30 patients ( 60 %) had  papilledema and 20 
patients (40%)  had  no features of  papilledema
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13 : Spectrum of Papilloedema  
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Table 
FOCAL DEFICITS
NO 
YES 
TOTAL 
 
                    Graph 11
   In our study population of 50 patients, 30  ( 60 %) had no evidence of 
focal deficits and 20 ( 40 %) had focal  neurological deficits .
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14: Profile of Focal Deficits 
 FREQUENCY % 
30 60.0 
20 40.0 
50 100.0
: Spectrum of Focal Deficits 
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Table 15: Sinuses Involved 
SINUS INVOLVED NUMBER PERCENTAGE 
Superior Sagittal Sinus 35 70% 
Transverse sinus 20 40% 
Sigmoid Sinus 25 50% 
Straight Sinus 6 12% 
Cortical veins 12 24% 
 
Graph12: Sinuses Involved 
 
         In our study ,most common sinus involved is superior sagittal sinus 
(70%),followed by sigmoid sinus (50%),transverse sinus (40%),cortical 
veins (24%) and straight sinus (12%). 
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INVESTIGATIONS:
                                       
D DIMER 
NEGATIVE
POSITIVE 
TOTAL 
 
                                 Graph 
Among the study population of  50 patients with CVT , 39  (78%) had 
positive D DIMER value which is above 500 ng / ml .The remaining 11 
(22%) patients had negative D DIMER values .
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Table 16: D Dimer Distribution  
FREQUENCY % 
 11 22.0 
39 78.0 
50 100.0 
13: D Dimer Distribution  
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Table 17
ds DNA 
NEGATIVE
POSITIVE
TOTAL 
 
Graph 
    43 patients (86 %) in the s
7 patients   (14 %) had positive ds
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: Spectrum Of Double Stranded DNA 
FREQUENCY % 
 43 86.0 
 7 14.0 
50 100.0 
14: Distribution of ds DNA 
tudy population ,had negative ds DNA , and 
 DNA . 
NEGATIVE POSITIVE
 
                                TABLE 
APLA 
NEGATIVE
POSITIVE 
TOTAL 
                                      
Graph 
APLA syndrome was positive in 7  (14 %) out of 50 
patients had associated SLE .
ANTI PHOSPHOLIPID ANTIBODY
NEGATIVE
80 
18: Spectrum of APLA  
FREQUENCY % 
 43 86.0 
7 14.0 
50 100.0 
 
15: Spectrum of APLA 
patient. Out of these   
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TABLE 
HOMOCYSTEINE
NEGATIVE
POSITIVE
TOTAL
 
Graph  
 Out of 50 patients , in whom homocysteine 
%) were found to have elevated homocysteine levels .
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19: Hyperhomocysteinemia in CVT 
 FREQUENCY % 
 35 70.0 
 15 30.0 
 50 100.0
16: Hyperhomocysteinemia in CVT 
were tested, 15 patients (30 
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Table 20
CT BRAIN
ABNORMAL
NORMAL
TOTAL 
                                       
Graph 
 
 
             Among the 50
Brain and 25 patients had abnorm
empty delta sign and features of  hemorrhagic  infarct.
 
 
NORMAL
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82 
: Neuro Imaging Studies – CT Brain 
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 25 50.0 
 25 50.0 
50 100.0 
 
17:  CT Brain Abnormality 
 population studied,   25 patients had normal CT 
al CT Brain findings such as co
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50%
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rd sign, 
                                       
ONSET 
UPTO 7 DAYS
ABOVE 7 DAYS
TOTAL 
                          
Graph 
   Out of 50 patients  , 40 patients ( 80 %) of the study population , had an 
early onset of symptoms within a period of 7 day.
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Table 21 : Onset Range  
FREQUENCY % 
 40 80.0 
 10 20.0 
50 100.0 
18: Onset of Symptoms  
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Table  22
 
ds 
DNA 
NEGATIVE 
Count
% within 
D DIMER
POSITIVE 
Count
% within 
D DIMER
Total 
Count
% within 
D DIMER
  
Graph 19
            Out of the 7 dS DNA positive cases, 6 cases are found to have D 
DIMER positive . Out of the 43 negative ds DNA  Patients 33 have D 
Dimer positivity and 10 D Dimer 
positive correlation with ds DNA and D Dimer in this stu
84 
:  Correlation of D Dimer and ds DNA
D DIMER 
Total
NEGATIVE POSITIVE 
 10 33 43 
 
90.9% 84.6% 86.0%
 1 6 7 
 
9.1% 15.4% 14.0%
 11 39 50 
 
100.0% 100.0% 100.0%
: Correlation of D Dimer and ds DNA 
 negativity. There is no significant 
dy. 
 
 
P Value 
0.595 
 
 
 
 
Table  23
 
APLA 
NEGATIVE 
Count
% within D 
DIMER
POSITIVE 
Count
% within D 
DIMER
Total 
Count
% within D 
DIMER
Graph  20
Out of the 7 positive case of APLA , all the 7 positive cases had D 
Dimer positivity and out of the 43 negative APLA , 32 had D Dimer 
positive and 11 had D Dimer 
correlation with D Dimer and APLA in this study.
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: Correlation of APLA and D Dimer 
D DIMER 
NEGATIVE POSITIVE 
 11 32 
 
100.0% 82.1% 86.0%
 0 7 
 
0.0% 17.9% 14.0%
 11 39 
 
100.0% 100.0% 100.0%
 
: Correlation of APLA and D Dimer 
negative. There is no significant positive 
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Table 24: Correlation of D Dimer and Homocysteine
 
HOMO 
NEGATIVE 
Count
% within D 
DIMER
POSITIVE 
Count
% within D 
DIMER
Total 
Count
% within D 
DIMER
 
                Graph 21: Correlation of D Dimer and Homocysteine 
        
              In   this study , 15 patients
Out of these 14 had D Dimer
patients had D Dimer positive.
between D Dimer and homocysteine in this study.
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 1 14 
 
9.1% 35.9% 
 11 39 
 
100.0% 100.0% 
 have elevated homocysteine levels.
  positive. Out of the 35 negative cases 25 
 There is no significant positive correlation 
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Table 25: Correlation of 
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Graph 22: Correlation of D Dimer With CT Brain 
The D Dimer and CT brain has a strong positive correlation in  our study.
in our study , there is positive findings in 50 % of the study group.
25 patients , out of the 25 negative CT patients ,24  patients had positive 
D Dimer .This implies that eventhough CT may be normal , D Dimer is 
elevated in majority of population .So  D Dimer can be used as an initial 
diagnostic bio marker in diagnosing  CVT.
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Total 
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     P Value  
0.002 
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Table 26: Correlation of D Dimer and Onset of Symptoms
 
ONSET 
RANGE 
Upto 7 
days 
Count
% within 
D DIMER
Above 7 
days 
Count
% within 
D DIMER
Total 
Count
% within 
D DIMER
           
Graph 23: Correlation of D Dimer and Onset of Symptoms
       The D Dimer was positive in  patients who presented early .Out of 
the 40 D Dimer  positive patients , 39 patients presented to us within 7 
days . There is a significant positive correlation between between D 
Dimer and onset of symptoms in our study.
diagnostic marker in CVT.
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Table  27 :CORRELATION OF D DIMER WITH MRI/MRV :  
 
 
 D DIMER  
TOTAL 
 
 
 
 
P VALUE - 
0.034 
HIGHLY 
SIGNIFICANT 
 
NEGATIVE POSITIVE 
 
MRV 
 
No of 
Sinuses 
involved 
1 7 12 19 
2 4 8 12 
3 0 15 15 
4 0 4 4 
TOTAL 11 39 50 
 
 
                 Graph 24: Correlation Between MRV and D Dimer  
 
 
 
 
 
        In this the correlation between MRV and D DIMER is highly 
significant .if there is a single sinus involvement the positivity of d dimer 
is less. When the number of sinus involvement is more , the positivity of 
d dimer is high.since d dimer is positive in most of the sinus involvement, 
it can be used as an initial diagnostic bio marker in CVT . 
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AREA UNDER THE CURVE – ROC CURVE 
 
 
 
The values in the ROC  curve indicates that there is a positive correlation 
between the variables mentioned  as shown in the table and curve above. 
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                          DISCUSSION  
                This section contains the comparison of the results of this study 
with various studies conducted earlier. 
                   TABLE 28:  Sex distribution compared to other studies  
STUDIES MALE : FEMALE 
Present study 1:1.3 
Srinivasan et al 1: 1.04 
Daif et al 1:1.3 
Agarwal DS et al 1:1.38 
Mehta SR 1:1.4 
                    
    The ratio of the male and female population in this study was 1:1.3 
and  this closely correlated with the ratio obtained in the study carried out 
by Daif , where the ratio was 1:1.3.Similar observations are observed in 
the studies conducted by Agarwal et al and Mehta et al . 
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TABLE 29:  Age distribution compared to other studies 
Study Age 
Present study 34.82 
Tarek gounda et al 36.2 
M.ghaffarpour et al 31.2 
Isabelle et al 36.2 
Khealani et al 35.4 
Tharaknath et al 22 
Nagaraja et al 32.3 
 
              The mean age in this study is 34.8 .Previous studies conducted 
by Tarek, Ghaffarpour, Isabelle, Khealani, Nagaraja et al are 36.2, 31.2, 
36.2, 35.4 and 32.3 respectively . The study conducted by Tharaknath  et 
al showed a mean age distribution of 22. By this we can conclude that 
CVT mainly occurs in younger population and mostly in their early 30 ‘s. 
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CLINICAL PROFILE  
        Table 30:  Comparing Headache With Other Studies  
HEADACHE PERCENTAGE (%) 
Present study 96 
Biousse et al 82 
Katrak et al 73 
Neki S  et al 85.5 
STROLZ et al 73.4 
Mehta SR et al 77.8 
 
       The fact that CVT has a varied presentation is depicted in our study 
also. In this study the most common presenting symptom was headache 
which was observed in 96 % of the study group. This was compared with 
the study conducted by Biousse et al with the presence of headache in 82 
% and by katrak et al with 73 %. NEKI S , strolz E , and Mehta et al 
demonstrated the incidence of headache around 85.8,73.4 and 77.8 % 
respectively. This explains that headache is the most common 
manifestation in CVT. The D Dimer was positive in most of the patients        
with headache. The  patients with negative D Dimer values had only 
features of      isolated headache and presented with a late presentation. 
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Table 31:   Comparing Seizures With Other Studies 
STUDIES PERCENTAGE 
Present study 34% 
Nagaraja  et al 56% 
Biousse et al 39% 
Katrak et al 58% 
Strolz E  et al 39.2% 
 
      Seizures was observed in 34 % of our study population. The study 
conducted by Nagaraja et al and katrak et al showed the incidence of 
seizures as 56 % and 58% respectively. Biousse et al showed an 
incidence of around 39 % which closely correlates with our study. A 
study conducted by strolz et al demonstrated the occurrence of seizures in 
39.2 % . 
               Table 32: Comparing  Sensorium With Other Studies 
STUDIES PERCENTAGE 
Present study 26% 
Nagaraja et al 50% 
Katrak et al 42% 
Biousse et al 52% 
95 
 
 
    Altered sensorium was found in 26 % of the patients in our study 
of 50 patients. Nagaraja et al reported an incidence of altered sensorium 
of 50% ,katrak et al of 42 % and Biouse et al of around 52 %.Compared 
to other studies , the incidence of seizures is low in our study. 
Table 33: Comparing Papilloedema with Other Studies 
STUDIES PERCENTAGE 
Present study 60% 
Biousse et al 51% 
Katrak et al 55% 
Tharakanth et al 47% 
Kumar s et al 32% 
Neki et al 80% 
Strolz et al 30% 
 
           In our study, a significant proportion of patients had evidence of 
papilloedema at the initial presentation of around 60 %.Our observations 
are related to the studies conducted by  katrak et al of 55%.The other 
studies conducted by Biousse, Tharakanth showed an incidence of 51 and 
96 
 
47 %.similar observations were noted in the studies conducted by kumar s 
et al ,Neki et al  and strolz et l with  32 % , 80 5 and 30 % respectively . 
Table 34: Comparing Focal Deficits With Other Studies 
Studies Percentage (%) 
Present study 40% 
Daif  et al 27% 
Strolz et al 56.9% 
Kumar s  et al 66% 
 
    The focal neurological deficits were noted in 40 % of our study 
population. Daif et al reported an incidence of 27 % ,whereas strolz et al 
and kumar s et al showed an incidence of around 56.9 % and 66 % 
respectively 
Table 35: Comparing Cranial Nerve Palsy With Other   Studies 
Present study Daif  et al 
22 14% 
 
The cranial nerve involvement is around 22 % in  our study and in a study 
conducted by daif et al is aroud 14 %. 
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Table 36: Comparing Sinus Involvement In CVT 
 Present 
study 
Christo 
et al 
Wysokinska 
et al 
Breteau 
et al 
Strolz  
et al 
T S  40 73 68 69% 38 % 
Sigmoid 
sinus 
50 - - - - 
SSS 70 53 55 67% 72.2 
                
   In our study the commonest sinus involved  was the superior 
saggital sinus (70%) followed by the sigmoid sinus (50%) , then by the 
transverse sinus (40%).Most of the patients in our study group had 
involvement of more than 1 cortical venous sinuses. The studies 
conducted by Christo et al demonstrated the presence of transverse 
sinus(73%) and superior sagittal sinus  (53%).Similar findings were 
reported in the studies conducted by Wysokinska et al .The study by 
breteau et al demonstrated the prevalence of transverse sinus involvement 
(69%) and superior sagittal sinus  (67%) .the study conducted by strolz et 
al  has the same rate of involvement of sinuses compared to our study. 
The involvement of more than 1 dural sinus has more D Dimer positive 
value compared to a single sinus involvement. This explains that D Dimer 
values depends upon the extent of thrombus involvement. 
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CT BRAIN ;  
     The commonest and the initial modality of  radiological tool used in 
our study is the CT Brain. Out of the 50 patients included in our study, 
CT was normal in 50 % of the patients.The remaining 50 % of the 
patients showed features of hemorrhagic infarct , delta sign , cord sign. 
Table 37: Comparing CT Findings With Other Studies 
 Present study Nagaraja  et al Dixit et al 
Hemorrhagic 
infarct 
39 40.9 48.4 
Non 
hemorrhagic 
infarct 
42 51.6 32.3 
Empty delta 
sign 
17 32 32 
 
     The most common finding in the present study is non hemorrhagic 
infarct (42%). Similar observations are noted in the studies conducted by 
nagaraja et al and dixit et al . 
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 Table  38: Comparing APLA With CVT  
Studies Percentage (%) 
Present study 14 
Katrak et al 38.5 
Christopher et al 22.6 
Chandrashekhara et al 14.2 
Carhuapoma et al 8 
   
In our study , 14 % of patients had a positive profile of APLA , which is 
in close relation to the study conducted by chandrashekara. Other studies 
conducted by katrak ,Christopher and carhuapoma showed positivity of 
around 38.5 ,22.6 and 8 % respectively .     
Table 39: Comparing D Dimer and CVT 
Studies Percentage  (%) 
Present study 78 
Misra  et al 77 
Wildberger et al 100 
Lalive et al 83 
Tarek et al 85.7 
Isabellee et al 90 
 
100 
 
   In our study , D Dimer was positive in 78 % of the patients. Out of 
50patientss 39 had  positive D Dimer values. The study conducted by 
wildberger showed a positivity of 100 %.Misra et al conducted a study  
on D Dimer ,the results of which are similar to our study. Isabelle et al , 
lalive te al tarek et al and m ghaffarpour et al showed the positivity of 90 
,83 , 85.7 and 95.3 % respectively. In our study there is a significant 
correlation between D Dimer and the findings in MRV . 
Table 40: Comparing Hyperhomocystinemia In Cvt 
Studies Percentage (%) 
Present study 30 
Cantu et al 37.8 
Martinelli et al 27.27 
 
    In our study hyperhomocysteinemia was present in 30 % of the 
study population. This in correlation with the studies conducted by cantu 
et al and martinelli et al Hyper homocystenemia is an important cause of  
hpercoagulability  and it increase the risk of CVT 4 fold. Therefore it is 
important to assay Homocysteine levels in the initial  prothrombotic  
workup for venous thrombosis. 
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ETIOLOGY IN CVT ; 
    In our study the etiology of CVT  is varied. Out of the 50 patients the 
etiology of 14 patients could not be found out. OCP  is the cause in  4 
patients . Homocysteine was positive in 15 patients . Out of the rare cause 
protein C & S deficiency has been documented .Dehydration causes CVT 
in 2 patients. HIV, Orbital cellulitis, varicella, meningitis each contributes 
to 1 case. Mastoiditis cause CVT  in 3 patients. Connective tissue 
disorders like  SLE  contribute to 5 cases. Tharakannth et al studied 15 
out of 49 cases having a predisposing  prothrombotic states in CVT.  
Majority of cases document a  hypercoagulable state, a full prothrombotic 
work up is essential in diagnosing the cause of CVT. 
EARLY ONSET OF CVT AND D DIMER : 
     In our study there is a strong relationship between the D Dimer values 
and the duration of presentation of the patient .The D Dimer is positive in 
39 patients out of the 50 patients included in our study population. All the  
D Dimer positive patients are presented to us within 7 days of symptoms 
onset .Negative D Dimer in CVT  patients is attributed to  a decrease D 
Dimer value after a certain period of time.This implies that D Dimer can 
be used as a diagnostic biomarker if the patients present early. In our  
study there is a positive correlation between the early onset of CVT and 
the D Dimer levels. 
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D DIMER AND MRV :  
      D Dimer  has a strong  relationship with the MRV findings . in our 
study, all the    D Dimer positive patients had features of CVT in MRI. 
The association between D Dimer and  MRI is statistically significant in 
our study. This study implies that though MRI / MRV is the diagnostic 
modality for CVT, the presence of D Dimer positivity can be taken as 
positive sign of CVT .Negative D Dimer assay excludes the presence of 
thrombosis with a high certainity and MRI / MRV should be preferably 
used only in patients with positive D Dimer test and highly suspected 
cases. 
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SUMMARY 
    This study was undertaken to study the usefulness of D Dimer as 
an initial diagnostic bio marker in cerebral venous thrombosis. A total of 
50 patients were studied over a period of one year .The salient features in 
our study are highlighted below: 
1. The mean age of presentation in our study is 34.82 . 
2. There is a slight female preponderance in our study .The sex ratio 
was 1.3 :1. 
3. The most  common presenting feature is headache (96%)  though 
non specific, followed by seizures (34%),altered sensorium 
(26%).The most common sign is papilledema (60%) followed by 
focal deficits (40%) 
4. Isolated headache has a negative D Dimer value   
5. The commonest sinus involved is superior sagittal sinus 
(70%),followed by sigmoid and transverse sinus.Most of the 
patients had more than one sinus involvement. 
6. CT Brain was normal in 50 % of the patients. 
7. Inherited Thrombophilias contribute to around 23 %  of patients 
with CVT. The most common in our study is 
Hyperhomocystenemia. 
8. No cause is identified in 14 patients. 
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9. D Dimer  was positive in 78 % of the patients with CVT.D Dimer 
has a high sensitivity when presented early  
10. D Dimer and MRV has a significant correlation. So in early 
diagnosis of CVT , D Dimer can be used as a diagnostic tool.MRI / 
MRV being a superior modality than CT, should be used in 
patients suspected of having CVT. 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
CONCLUSION 
• Positive D Dimer test with high sensitivity and negative predictive 
value may be a useful diagnostic modality in suspected CVT 
patients  
• Normal value of D Dimer makes the diagnosis of CVT unlikely 
• MRI should preferably be done only in patients with positive D 
Dimer test and highly suspected cases. 
• Further studies are needed to  highlight the importance of D Dimer 
in CVT. 
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PROFORMA 
Name        :                                       IP  NO :  
Age            :                                         DOA: 
Sex              :                                   DOD /E : 
Occupation :                                 Education : 
Address : 
Socioeconomic status : 
Clinical diagnosis :  
Present complaints : 
1. Headache  
2. Seizures 
3. Vomiting 
4. Altered sensorium 
5. Weaknes of limbs  
6. Visual disturbances  
7. Fever 
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8. Sensory symptoms  
9. Speech difficulties 
SIGNS : 
1. Consciousness 
2. Raised ICT 
3. Cranial nerve palsies 
4. Focal deficits 
5. Sensory deficits 
PAST HISTORY : DM/ HT/ TB/ CAHD / SEIZURES/ OCP   
                                Intake ,  venous thrombosis 
FAMILY HISTORY : Similar illness  
GENERAL EXAMINATION  
1. Anemia 
2. Jaundice 
3. Clubbing  
4. Pedal edema 
5. Lymphadenopathy 
6. Signs of dehydration  
7. Purpura  / rash  
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VITAL SIGNS : 
1. Pulse 
2. Blood pressure 
3. Respiratory rate  
4. Temperature 
NEUROLOGICAL EXAMINATION : 
1. Glassgow coma scale 
2. Mini mental status examination 
3. Higher mental functions 
4. Cranial nerves with fundus examination  
5. Motor power  
6. Tone 
7. Reflexes – superficial , deep 
8. Plantar  response 
9. Sensory system 
10. Cerebellum 
11. Speech  
12. Gait 
13. Autonomic system 
14. Meningeal signs 
15. Spine and cranium 
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16. Other system examination  
        CVS , RS,GIT,ENT,OPHTHALMOLOGY  
INVESTIGATIONS : 
1. Complete blood count  
2. Blood sugar  
3. Renal function test  
4. Liver function test  
5. Peripheral smear  
6. Urine routine  
7. Coagulation profile   
8. ECG  
9. X-Ray chest  
10. CT Brain  
11. MRI / MRV Brain  
12. ANA  
13. APLA 
14. Serum Homocysteine  
15. D DIMER 
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CONSENT FORM 
Mr/Mrs/Ms………………………………………………………….…….
S/W/D of…………………………………………(legal guardian) is being 
asked to be a participant in the research study titled ““ A Study on 
Evaluation of  plasma D-DIMER as an initial Diagnostic Biomarker in 
Cerebral Venous Thrombosis ”” in CMC Hospital, Coimbatore, He /she 
satisfies eligibility as per the inclusion criteria. You (legal guardian) can 
ask any question you may have before agreeing to participate. 
Research Being Done 
A STUDY ON  Evaluation of plasma D-DIMER as an initial Diagnostic 
Biomarker in Cerebral Venous Thrombosis. 
Purpose of Research 
           Aim of the study is to evaluate the role of plasma D-DIMER as 
an initial Diagnostic Biomarker in Cerebral Venous Thrombosis. 
Procedures involved 
       It includes details like age, sex and about history of the problem and 
associated risk factors as well as clinical examination. 
       Investigations includes complete hemogram, renal function 
tests(blood urea, serum creatinine), blood sugar, lipid profile ,coagulation 
profile, MRI- BRAIN . 
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Decline from Participation 
You have the option to decline from participation in the study  existing 
protocol for your condition. 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
Authorization to publish Results   
Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified. 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to 
me, and  I may ask questions at any time. 
 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(volunteer)   
 
--------------------------------                          -------------------------------- 
Signature of witness                                               Date 
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xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :        taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;Jtj; 
Jiwapy; gl;l gapYk; khztp mth;fs; nkw;bfhs;Sk;  
"\isapd; ,uj;jf;FHha; ciwa[k; jd;ikia; ; ; ; [ ; ;; ; ; ; [ ; ;; ; ; ; [ ; ;  (CVT) mstpl o-
ilkiu Kjy; epiy fUtpahf gad;gLj;jyhkh>; ; ;; ; ;; ; ; " Fwpj;j 
Ma;tpy; bra;Kiw kw;Wk; midj;J tptu';fisa[k; nfl;Lf; 
bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; 
vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j Ma;tpypUe;J ehd; tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk;  :       ifbahg;gk; / nuif 
ehs; : 
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KEY TO MASTER CHART 
OCCU   –  OCCUPATION 
HA    –  HEADACHE 
CON    –  CONVULSION 
VOM   -  VOMITING 
LOC    –  LOSS OF CONSCIOUSNESS 
CN    –  CRANIAL NERVE INVOLVEMENT 
PAP    –  PAPILLEDEMA 
FD   -  FOCAL DEFICITS 
DS DNA   –  DOUBLE STRANDED DNA 
APLA  -  ANTI PHOSPHOLIPID ANTIBODY 
HOMO   –  HOMOCYSTEINE 
CT    –  COMPUTED TOMOGRAPHY 
MRV   -  MAGNETIC RESONANCE VENOGRAPHY 
HW    –  HOUSEWIFE 
C   -  COOLY 
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STU    –  STUDENT 
ENG    –  ENGINEER 
LOR DRI   –  LORRY DRIVER 
SSS   -  SUPERIOR SAGITTAL SINUS 
SS   -  SIGMOID SINUS 
TS    –  TRANSVERSE SINUS 
STS    –  STRAIGHT SINUS 
F   -  FEMALE 
M   -  MALE 
CTD    –  CONNECTIVE TISSUE DISORDER 
OCP    –  ORAL CONTRACEPTIVE 
CV    –  CORTICAL VEIN  
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 S.NO NAME AGE SEX IP NO OCCU HA CON VOM LOC CN FEVER PAP FD ONSET D DIMER DS DNA APLA HOMO CT MRV ETIOLOGY
1 BHUVANA 26 F 21654 HW YES NO YES NO NO NO YES NO 2 POSITIVE NEGATIVE NEGATIVE POSITIVE NORMAL SSS,SS HOMO
2 VEERARAGAVAN 46 M 12685 C YES YES YES YES NO NO YES YES 1 POSITIVE NEGATIVE NEGATIVE POSITIVE ABNORMAL SSS,SS,TS HOMO
3 FRANCIS 30 M 23421 BUS YES NO YES NO YES NO NO YES 2 POSITIVE NEGATIVE POSITIVE POSITIVE ABNORMAL SSS,TS,CV APLA
4 RANGAN 45 M 32431 C YES YES YES NO YES YES YES YES 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SSS VARICELLA
5 AJITH 19 M 26542 STU YES NO NO NO NO NO YES NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL TS,SS,CV TRAUMA
6 SARASWATHI 28 F 23487 HW YES NO YES NO NO NO NO NO 8 NEGATIVE POSITIVE NEGATIVE NEGATIVE NORMAL SS SLE
7 RAMU 28 M 29654 C YES NO NO NO NO YES YES NO 3 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL TS,SS,CV MASTOID
8 MANJULA 26 F 12876 HW YES NO NO NO NO NO NO NO 3 POSITIVE NEGATIVE NEGATIVE POSITIVE ABNORMAL SSS,TS,CV HOMO
9 JANSI 36 F 32143 HW YES YES YES YES NO NO YES YES 2 POSITIVE POSITIVE NEGATIVE NEGATIVE NORMAL SSS,SS CTD
10 DINESH 31 M 23135 Bank YES NO NO NO NO NO NO NO 8 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL TS,SS MASTOID
11 PRIYA 26 F 27432 CLERK YES NO YES NO NO NO YES NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS OCP
12 MATHI 62 M 31242 ENG NO NO NO NO YES NO YES YES 8 NEGATIVE NEGATIVE NEGATIVE POSITIVE NORMAL SSS HOMO
13 SANGEETHA 38 F 27432 HW YES NO YES NO NO NO NO NO 2 POSITIVE NEGATIVE NEGATIVE POSITIVE ABNORMAL TS,SS,CV HOMO
14 GOWRI 25 F 31743 MANAGER YES NO YES NO NO YES YES YES 1 POSITIVE POSITIVE POSITIVE POSITIVE ABNORMAL SSS,SS,STS APLA
15 ARUMUGAM 46 M 21097 C YES NO NO NO NO NO NO NO 7 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS         -
16 GIRIJA 28 F 21075 HW YES YES YES YES NO NO YES YES 1 POSITIVE POSITIVE NEGATIVE NEGATIVE NORMAL SSS ,TS,SS SLE
17 SURYA 14 M 31276 VENDOR YES NO YES NO YES YES NO NO 1 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS,TS,CV
ORBITAL 
CELLULITIS 
18 UMA 38 F 39567 HW YES NO NO NO NO NO NO NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SSS OCP
19 GOPALSAMY 68 M 32178 C YES NO YES NO NO NO NO NO 3 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SS DEHYDRATION
20 RAMYA 31 F 19306 HW YES NO NO NO NO NO YES NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS OCP
21 BRINDHA 39 F 16209 HW YES NO NO NO NO NO NO NO 9 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS,CV        -
22 RAJAMMAL 62 F 20419 HW YES YES YES NO NO YES NO NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS,SS DEHYDRATION
23 PRABHU 29 M 31035 BANK YES NO NO NO NO NO NO NO 8 NEGATIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SSS,TS      -
24 SINGARAM 43 M 21745 LOR DRI YES YES YES YES YES YES YES YES 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SSS,ST S,SS,TS HIV
25 SAROJA 36 F 21836 HW YES YES YES YES YES YES YES YES 2 POSITIVE POSITIVE POSITIVE POSITIVE ABNORMAL SSS,ST S,SS,TS SLE
MASTER CHART 
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26 CHITRA 29 F 21644 TYPIST YES NO YES NO NO NO NO NO 2 POSITIVE NEGATIVE NEGATIVE POSITIVE ABNORMAL SSS,STS,CV HOMO
27 GOPAL 37 M 30912 C YES YES YES NO NO NO YES NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SS,CV     -
28 AKILA 31 F 20198 TEACHER YES YES YES NO YES YES YES YES 2 POSITIVE POSITIVE POSITIVE POSITIVE ABNORMAL SSS,SS,TS,STS PROTEIN S 
29 MUTHAIYAN 54 M 10286 C YES NO NO NO YES YES YES YES 8 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS     -
30 GAYATHRI 25 F 10357 HW YES NO YES NO NO NO YES YES 2 POSITIVE POSITIVE NEGATIVE NEGATIVE ABNORMAL SS,TS,STS,CV CTD
31 RAVI 32 M 20194 C YES YES YES YES NO YES YES YES 2 POSITIVE NEGATIVE NEGATIVE POSITIVE NORMAL SS HOMO
32 ANNAMMA 43 F 38413 HW YES NO NO NO NO YES NO NO 8 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL TS,STS      -
33 KUMAR 62 M 21964 C YES YES YES YES NO NO YES YES 1 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SSS,SS,TS METASTASIS
34 GEETHA 28 F 19632 STU YES NO NO NO NO NO YES NO 1 POSITIVE NEGATIVE POSITIVE NEGATIVE ABNORMAL SSS,STS APLA
35 SOWMIA 26 F 23167 TYPIST YES NO NO NO NO NO NO NO 1 POSITIVE NEGATIVE NEGATIVE POSITIVE ABNORMAL SS,STS HOMO
36 BALAJI 34 M 15276 VENDOR NO YES YES YES NO NO YES YES 4 POSITIVE NEGATIVE NEGATIVE POSITIVE ABNORMAL SSS,TS,CV HOMO
37 SASI 39 F 31356 HW YES NO NO NO NO NO NO NO 10 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS      -
38 DEVI 40 F 19524 C YES YES NO YES NO NO YES YES 4 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL STS,SS     -
39 ELAKIYA 23 F 13334 LAWYER YES NO YES NO NO NO NO NO 2 POSITIVE NEGATIVE POSITIVE NEGATIVE ABNORMAL SSS APLA
40 GIRIDAR 46 M 20000 C YES YES YES YES YES YES YES YES 3 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SS        -
41 AMBIKA 43 F 23433 HW YES NO YES NO NO NO YES NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SS,TS,CV MASTOID
42 MEERA 34 F 10293 HW YES NO NO NO NO NO YES YES 2 POSITIVE NEGATIVE NEGATIVE POSITIVE NORMAL SSS HOMO
43 CHINNADURAI 28 M 31232 LOR DRI YES YES YES YES YES YES YES NO 1 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS          -
44 KANIMOZHI 26 F 18346 TYPIST YES NO YES NO NO NO NO NO 4 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SSS,SS,TS MENINGITIS
45 SUDHA 34 F 32133 HW YES NO NO NO NO NO NO NO 8 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS          -
46 JAMES 26 M 12322 C YES NO YES NO YES NO YES YES 3 POSITIVE NEGATIVE POSITIVE POSITIVE ABNORMAL SSS PROEIN C ,S
47 LAKSHMI 39 F 23109 HW YES YES YES YES NO NO YES NO 2 POSITIVE NEGATIVE NEGATIVE NEGATIVE ABNORMAL SSS,SS,CV         -
48 NARASIMMAN 45 M 10098 COBBLER YES NO NO NO NO NO NO NO 8 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS         -
49 REKHA 31 F 31795 HW YES NO YES NO NO NO YES NO 3 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SSS OCP
50 BALU 31 M 18264 C YES YES YES YES NO YES YES YES 3 POSITIVE NEGATIVE NEGATIVE NEGATIVE NORMAL SS,TS         -
 
